Adolor Corp

Adolor — Technical Presentation (October 2003)

12 slides from Adolor's technical presentation, Oct 23, 2003

  1. Slide 1: Results from Alvimopan Phase 3 Clinical Safety Study 14CL306

    Results from Alvimopan Phase 3 Clinical Safety Study 14CL306

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements This oral presentation and the questions and answers that follow contain forward-looking statements including but not limited to the following: • Our financial condition • Our plans to submit alvimopan clinical studies 306, 302 and 313 in an NDA • Our target dates for comp

  3. Slide 3: Alvimopan for the Management of Postoperative Ileus

    Alvimopan for the Management of Postoperative Ileus Study N Primary Objective Population Efficacy Colon Resection; Radical Hysterectomy; Simple Hysterectomy (22%) * Efficacy Colon Resection; Small Bowel Resection; Radical Hysterectomy; Simple Hysterectomy (14%*) Efficacy Colon Resection; Small Bowel

  4. Slide 4: Primary Objective

    • Primary Objective : Ø To evaluate the safety of alvimopan administered twice daily for seven postoperative days in patients undergoing total abdominal simple hysterectomy in a placebo-controlled observational safety study • These patients were evaluated both in the Hospital, as well as when they w

  5. Slide 5: Study design: double-blind, placebo-controlled, randomized, multi-center

    • Double-blind, placebo-controlled, randomized, multi-center • All patients underwent a Total Abdominal Simple Hysterectomy • 519 patients enrolled across 2 treatment groups in a 4 to 1 ratio: 413 on alvimopan 12 mg and 106 on placebo • Patients were to receive their first dose at least two hours pr

  6. Slide 6: Overview

    Overview Simple Hysterectomy patients, as compared to patients undergoing Bowel Resection, are: • fed sooner, • have flatus sooner, and • discharged home from the Hospital sooner, often before they have a bowel movement

  7. Slide 7: Primary Objective: Safety and Tolerability

    • Primary Objective : Ø Alvimopan was generally well tolerated Ø Most frequent adverse events were : Placebo 12 mg (N = 106) (N = 413) Nausea 64.2 % 72.6 % Vomiting 25.5 % 31.5 % Constipation 31.1 % 23.0 % Discontinuations for adverse events: Total 4.7% 3.9%

  8. Slide 8: Summary of Secondary Objective

    Summary of Secondary Objective Mean in hours Time to: Alvimopan Placebo Difference First Flatus 43.2 46.7 3.5 First Solids 50.5 51.5 1.0 D/C Order 66.0 68.6 2.6 GI Recovery 54.2 55.4 1.2 First BM 71.8 93.1 21.3* “Solids In, Solids Out” 74.1 93.5 19.4* Responder 1 75% 72% *: Denotes Statistically Sig

  9. Slide 9: Secondary Objective: Time to First BM (In-Hospital Phase)

    Secondary Objective: Time to First BM (In-Hospital Phase) [GRAPH]

  10. Slide 10: Secondary Objective: Time to First BM (In-Study Phase)

    Secondary Objective: Time to First BM(In–Study Phase) [GRAPH]

  11. Slide 11: Summary

    Summary • Regarding the Primary Objective : Ø Alvimopan, 12 mg BID was generally well tolerated, both in the Hospital as well as at Home for the 7 Days of treatment • Regarding the Secondary Objective : Ø All efficacy endpoints showed a difference in favor of alvimopan Ø A difference for alvimopan 1

  12. Slide 12: Adolor Corporation

    adolor CORPORATION d@or

Adolor — Technical Presentation (October 2003) on 6ix